Midazolam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Midazolam — also known as Versed — is a synthetic depressant of the benzodiazepine class. It is 2–4 times as potent as diazepam, distinguished by water solubility that permits stable injectable formulations.[1] Midazolam is a non-selective positive allosteric modulator of GABA-A receptors,[2] amplifying the brain's primary inhibitory signaling without directly activating it.[3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
alprazolam, diazepam, lorazepam +5 morealprazolam, diazepam, lorazepam, clonazepam, alcohol, barbiturates, zolpidem, zopiclone show less
Synthesized in 1975 by Armin Walser and Rodney Fryer at Hoffmann-La Roche, midazolam was the first benzodiazepine engineered for water solubility — a structural innovation that eliminated the need for organic solvents in injectable formulations.[4] FDA-approved in 1985 as Versed, it became the standard short-acting parenteral benzodiazepine for procedural sedation and anesthesia induction. It remains on the WHO Model List of Essential Medicines, with an intranasal formulation (Nayzilam) approved in 2019 for acute seizure clusters.[5]
Subjective effects include sedation, anxiolysis, anterograde amnesia, muscle relaxation, and disinhibition. The experience is one of rapid erasure — anxiety dissolves, consciousness narrows to a drowsy present tense, and memory formation ceases before the subject recognizes sedation has taken hold. Paradoxical agitation, impaired judgment, and complete amnesia for events during the drug's action are characteristic unsought effects.
Midazolam produces physical and psychological dependence with regular use, and its primary acute danger — respiratory depression — becomes synergistically lethal when combined with opioids or alcohol. Tolerance develops through receptor-level adaptations[6][7] that take days to establish and weeks to reverse; an active metabolite that accumulates in kidney failure can cause prolonged sedation lasting days.[8] Extensive clinical use since 1985 provides a robust and well-characterized evidence base.
History[edit]
Discovery
The benzodiazepine class originated in Leo Sternbach's serendipitous discovery at Hoffmann-La Roche in 1955, leading to chlordiazepoxide (1960) and diazepam (1963).[9] Midazolam was synthesized two decades later, in 1975, by chemists Armin Walser and Rodney Fryer at the same company — designed from the outset as a water-soluble benzodiazepine. The fusion of an imidazole ring onto the benzodiazepine scaffold gave the molecule a pH-dependent switch: water-soluble in acidic solution for injection, lipid-soluble at body pH for rapid brain penetration.[4]
Clinical adoption
FDA-approved in 1985 under the brand name Versed, midazolam became the first benzodiazepine produced primarily for anesthesia.[10][11] Landmark pharmacology reviews by Reves, Dundee, and Kanto established its clinical profile and positioned it as the standard short-acting parenteral benzodiazepine for procedural sedation, premedication, and anesthesia induction.[12][13][4] The compound was listed on the WHO Model List of Essential Medicines, and in 2019 an intranasal formulation (Nayzilam) received FDA approval for acute seizure clusters in patients aged 12 and older.[5][14]
Controversy: lethal injection
In the 2010s, several U.S. states introduced midazolam into execution protocols after pentobarbital manufacturers restricted supply for that purpose. Critics — including co-inventor Armin Walser — argued that a sedative lacking true anesthetic properties cannot prevent awareness of painful execution drugs. In 2015, the U.S. Supreme Court upheld midazolam's use in executions in Glossip v. Gross.[10]
The brand name Versed derives from the Latin versus (turned), referencing the molecule's pH-dependent ring-opening that "turns" it between water-soluble and lipid-soluble forms. In clinical slang, "being Versed" has become a colloquial verb for receiving procedural sedation with amnesia — a shorthand reflecting the drug's ubiquity in procedural medicine. Midazolam's reliable anterograde amnesia has given it a dual cultural identity: in medical contexts it is valued for erasing procedural distress, while in forensic and media contexts it is associated with drug-facilitated assault and coercive compliance.
Chemistry[edit]
Structural class
Midazolam is the prototypical imidazobenzodiazepine — the first member of this structural subclass.[12] Classical 1,4-benzodiazepines such as diazepam and alprazolam share a seven-membered diazepine ring fused to a benzene ring. Midazolam adds an imidazole ring fused at the 1,2-position of the benzodiazepine scaffold, creating a tricyclic system.
This structural modification produces a pharmaceutically critical property: a pH-dependent conformational switch. Below pH 4, the imidazole nitrogen protonates and the diazepine ring opens, rendering the compound freely water-soluble in acidic injectable solutions. At physiological pH, the ring closes and midazolam becomes highly lipophilic, crossing the blood-brain barrier rapidly.[4][12]
This eliminates the need for organic cosolvents (propylene glycol, ethanol) required by Diazepam injectable formulations, reducing injection-site irritation and venous damage.[4]
Molecular properties
| Molecular formula | C₁₈H₁₃ClFN₃ |
| Molecular weight | 325.8 g/mol |
The scaffold comprises a chloro-substituted benzene ring at position 8, a seven-membered 1,4-diazepine ring bearing a 2-fluorophenyl group at position 6, and the fused imidazole ring with a methyl group at position 1. The fluorophenyl group contributes to receptor binding affinity, while the 8-chloro substituent influences potency relative to unsubstituted analogs.
Stereochemistry
Midazolam possesses planar chirality from the non-planar seven-membered diazepine ring, which creates two conformational enantiomers (Rp and Sp) that interconvert rapidly via ring flip at room temperature. Clinically, midazolam is used as a racemic mixture; no therapeutic advantage of individual enantiomers has been established.[10]
Physical properties
The free base is a white to yellowish crystalline powder; the hydrochloride salt is the standard pharmaceutical form. Water solubility is strongly pH-dependent: freely soluble below pH 4, practically insoluble at neutral pH. This profile is unique among clinically used benzodiazepines.[4]
Pharmacology[edit]
Mechanism of action
Midazolam is a positive allosteric modulator of the GABA-A — the brain's principal inhibitory ion channel. It binds at the interface between α and γ2 subunits, a site distinct from where GABA itself binds.[3] When GABA is present, midazolam increases the frequency of chloride channel opening, hyperpolarizing neurons and reducing their excitability. In the absence of GABA, midazolam has no direct effect on the channel.
Midazolam does not distinguish between the major GABA-A receptor subtypes (α1, α2, α3, α5-containing).[2] This non-selectivity means it produces the full spectrum of benzodiazepine effects simultaneously: sedation and amnesia (mediated by α1 subunits), anxiolysis and muscle relaxation (α2/α3), and cognitive impairment (α5). Unlike subtype-selective compounds under development, midazolam cannot produce anxiolysis without sedation.
Milligram for milligram, midazolam is approximately 2–4 times as potent as diazepam.[1]
Pharmacokinetics
Bioavailability varies substantially by route. Intravenous delivery is immediate and complete. Oral bioavailability is approximately 41–50% in young adults, reduced by extensive first-pass liver metabolism.[15] Intramuscular absorption is rapid and nearly complete (~90%). The intranasal formulation (Nayzilam) reaches approximately 44% bioavailability with onset within 3–5 minutes.[5] Buccal bioavailability ranges from 28% to 66% depending on mucosal contact time.[16]
Midazolam distributes rapidly into fatty tissue, explaining prolonged effects in obese patients (volume of distribution roughly tripled compared to lean controls).[17][15] Elderly patients show markedly slower clearance: half-life extends from approximately 2 hours in young adults to over 5 hours in elderly men and over 8 hours in men above 80.[15][17]
The liver metabolizes midazolam primarily through CYP3A4 to an active metabolite (1'-hydroxymidazolam) and an inactive one (4-hydroxymidazolam).[18][3] A further metabolite — the glucuronide conjugate of 1'-hydroxymidazolam — retains sedative activity and accumulates in kidney failure, causing prolonged sedation that may last days.[8][19] This effect is reversible with flumazenil.
Patients with liver cirrhosis show decreased clearance (approximately 37% reduction) and increased free drug fraction, requiring dose adjustment.[20]
Neuroscience[edit]
Where it acts
Midazolam-induced sedation operates through specific sleep-related circuits rather than blanket cortical suppression. The locus coeruleus–ventrolateral preoptic nucleus pathway plays a central role: GABA-A activation suppresses noradrenergic arousal signaling, and recovery of consciousness involves reactivation of this same circuit through α1-adrenergic receptors.[21] This means midazolam sedation is mechanistically closer to natural sleep than to the cortical disconnection produced by general anesthetics.
Anterograde amnesia — the signature cognitive effect — reflects selective disruption of hippocampal memory encoding. GABA-A receptor potentiation in the hippocampus (particularly via α5-containing receptors) suppresses long-term potentiation, blocking the transition from working memory to consolidated recall.[22] This explains why patients under midazolam follow commands and respond to questions but form no lasting memory of doing so.
Why it matters
The shared circuitry between midazolam sedation and natural NREM sleep positions benzodiazepine sedation within sleep neuroscience rather than anesthesia theory.[21] Separately, identification of specific gene variants (GABRB1 polymorphisms) that predict sedation depth and amnesia quality represents an emerging pharmacogenomic framework — suggesting that individual response variability has molecular substrates amenable to genetic testing.[23]
The molecular mechanisms of tolerance — transcriptional downregulation of GABA-A receptor subunits and receptor uncoupling through phosphorylation[6][7] — frame benzodiazepine tolerance as a gene-expression-level adaptation, not simple receptor fatigue. This explains both the gradual onset (days) and prolonged reversal (weeks) of tolerance.
Whether subtype-selective compounds can replicate midazolam's anxiolysis without its sedation and amnesia remains unresolved — no α1-sparing benzodiazepine has reached clinical approval.[24] The mechanism behind paradoxical excitatory reactions (agitation and combativeness in 1–15% of patients) is unknown, with proposed explanations ranging from subcortical disinhibition to genetic variation in GABA-A subunit expression.[25] The causal link between midazolam and ICU delirium also remains unclear — whether the drug directly disrupts neurotransmitter balance or the association reflects confounding by illness severity.[26]
Subjective Effects[edit]
Midazolam produces dose-dependent CNS depression along a continuum from light anxiolysis through conscious sedation to complete loss of consciousness. Route of administration profoundly shapes the experience: intravenous delivery produces near-immediate sedation with a narrow window between calm and sleep, while oral administration unfolds gradually, permitting an extended period of conscious relaxation. Anterograde amnesia — the loss of new memory formation — is the most distinctive experiential feature, occurring reliably even below the sedation threshold. Set and setting modulate the subjective quality: anxious patients in clinical environments often perceive the anxiolytic effects as disproportionately salient.
Within the benzodiazepine class, midazolam is faster-acting and shorter-lived than diazepam, with more reliable amnesia at comparable doses. Compared with lorazepam, its rapid onset and shorter duration suit acute procedural contexts but make it less appropriate for sustained anxiolysis. Paradoxical excitatory reactions occur more frequently with midazolam than with longer-acting benzodiazepines.
Effect Grid
Moderate sedation with reliable anterograde amnesia defines this tier. Anxiety suppression is substantial — the individual feels calm and unconcerned. Cognitive impairment is evident: focus suppression, analysis suppression, and information processing suppression produce a state of comfortable mental quietude. Memory suppression is pronounced; new explicit memories are not being formed.
Physical effects include significant muscle relaxation and clear motor control impairment. Sedation manifests as drowsiness, though the individual typically remains responsive to verbal commands. Physical fatigue and bodily heaviness are common. Respiratory depression is present but usually subclinical in healthy individuals.
This is the standard procedural sedation range. The individual may appear conversant and cooperative yet have complete amnesia for the period afterward.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Proprioceptive distortion · Vestibular distortion · Touch suppression · Visual haze / noise · Visual processing suppression
Visual processing suppression
Bodily heaviness · Dizziness · Nystagmus (eye wobbles) · Breathing alteration · Body high · Yawning · Heart rate perception changes · Pain suppression · Dry mouth · Headache · Laughter fits · Nausea · Abnormal heartbeat · Involuntary body movements · Restlessness · Trembling · Vomiting · Bodily dissociation
Breathing alteration · Body high · Yawning · Heart rate perception changes · Pain suppression · Dry mouth · Headache · Laughter fits · Nausea · Involuntary body movements · Restlessness · Trembling · Vomiting · Bodily dissociation
Analysis suppression · Focus suppression · Information processing suppression · Memory fragmentation · Thought deceleration · Confusion · Creativity suppression · Delusions of sobriety · Motivation suppression · Thought disorganization · Aesthetic suppression · Language suppression · Pattern recognition suppression · Cognitive euphoria · Humor enhancement · Compulsive redosing urge · Amnesia · Delirium
Memory fragmentation · Thought deceleration · Confusion · Creativity suppression · Motivation suppression · Thought disorganization · Aesthetic suppression · Language suppression · Pattern recognition suppression · Cognitive euphoria · Humor enhancement · Compulsive redosing urge · Amnesia · Delirium
Anxiety · Dysphoria · Irritability
Sociability enhancement · Compulsive behavior reduction · Emotional susceptibility · Social connection · Craving · Depersonalization · Derealization · Cognitive disconnection
Craving · Depersonalization · Derealization · Cognitive disconnection
Timeline
Gradual emergence of calm as anxiolysis develops before sedation. A subtle sense of relaxation and reduced concern appears, distinct from placebo by the end of this phase.
Sedation and muscle relaxation build steadily. Anterograde amnesia begins — memory encoding weakens before drowsiness becomes obvious. Thought deceleration is noticeable.
Maximum sedation and amnesia. Full anxiolysis with cognitive impairment — focus suppression and analysis suppression are pronounced. Motor control impairment makes ambulation unsteady.
Gradual return of alertness and orientation. Amnesia may persist beyond the point of apparent recovery — the individual may seem alert but still not be encoding memories reliably.
Residual drowsiness and mild psychomotor impairment without euphoric quality. Reaction time and coordination remain subtly impaired.
⚠ Do not drive or operate machinery for at least 6 hours after oral midazolam administration, or longer if sedation persists.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- High
- Cross-tol.
- alprazolam · diazepam · lorazepam
Toxicity
Acute toxicity
Benzodiazepine overdose alone is rarely fatal in otherwise healthy adults with access to supportive care — the safety margin for isolated midazolam overdose is substantially wider than for opioids or barbiturates. Overdose symptoms include unsteady movement, involuntary eye movements, slurred speech, low blood pressure, excessive sedation, and breathing depression progressing to coma at extreme doses.
The safety margin narrows dramatically with co-administration of other CNS depressants. Opioid co-administration produces synergistic (not merely additive) breathing depression and is a major driver of benzodiazepine-related overdose deaths. Alcohol, barbiturates, and other benzodiazepines produce additive CNS depression.
Cardiovascular effects
Midazolam causes modest drops in blood pressure and mild increases in heart rate. These effects are generally insignificant in stable patients and substantially less pronounced than those produced by barbiturate induction agents, giving midazolam a relative cardiovascular safety advantage.[12]
Breathing depression
Dose-dependent suppression of breathing drive is the primary acute safety concern. The risk increases markedly when combined with opioids (synergistic effect) and in elderly patients.[3] Breathing monitoring and immediate access to ventilation support are mandatory during intravenous administration.
In the context of status epilepticus treatment, the rate of breathing depression with benzodiazepine administration is lower than in untreated patients, reflecting that breathing compromise is itself a consequence of uncontrolled seizures.[27]
Active metabolite accumulation
In patients with severe kidney failure, an active metabolite (1'-hydroxymidazolam glucuronide) accumulates and causes prolonged sedation that may persist for days — even when parent drug levels have fallen below therapeutic range. This effect is reversible with flumazenil.[8]
Reproductive toxicity
Animal studies show no embryotoxicity, birth defects, or genetic damage.[28] No controlled human studies in pregnancy exist. Neonatal exposure near delivery can cause sedation, low muscle tone, and breathing depression. Chronic maternal use may produce neonatal withdrawal.
Psychological risks
Anterograde amnesia occurs reliably at sub-sedating doses and intensifies with dose and age.[22] While therapeutically exploited in procedural settings, unintended amnesia in non-clinical contexts poses risks for informed consent and autonomous decision-making.
Paradoxical reactions — agitation, combativeness, restlessness, increased anxiety, and rarely rage — occur in approximately 1–15% of patients, most commonly in elderly individuals, children, and those with psychiatric conditions.[25]
Disinhibition at sub-anesthetic doses may manifest as impaired judgment, risk-taking behavior, and inappropriate social conduct. This effect contributes to misuse liability and is relevant to drug-facilitated assault contexts.
ICU delirium is associated with prolonged midazolam infusion. Clinical guidelines identify benzodiazepines as an independent risk factor for ICU delirium.[26]
Tolerance and dependence
Tolerance to sedative, anxiolytic, sleep-inducing, and anticonvulsant effects develops with repeated or continuous use. Two molecular mechanisms are established: downregulation of GABA-A α1 subunit genes[6] and receptor uncoupling through increased phosphorylation.[7]
Full cross-tolerance exists between midazolam and other benzodiazepines (alprazolam, diazepam, lorazepam), with partial cross-tolerance extending to alcohol, barbiturates, and Z-drugs.[7][29]
Physical and psychological dependence develop with regular use. Non-human primate studies confirm reinforcing properties and abuse liability.[24]
Withdrawal from chronic midazolam use can be life-threatening. Features include anxiety, agitation, insomnia, tremors, muscle cramps, heightened sensitivity to light and sound, seizures (potentially fatal), and psychosis in severe cases. Midazolam's short half-life makes abrupt discontinuation particularly dangerous. Standard management involves gradual taper using a long-acting benzodiazepine substitute (Diazepam or clonazepam).
Drug interactions
The most dangerous pharmacodynamic interaction is with opioids, producing synergistic breathing depression — a leading cause of benzodiazepine-related overdose deaths.
Alcohol produces additive CNS and breathing depression with midazolam. Concurrent use at peak effect is dangerous.[30]
CYP3A4 inhibitors dramatically increase midazolam exposure. Azole antifungals (ketoconazole, itraconazole, voriconazole) increase exposure 2–10-fold.[31] Macrolide antibiotics (erythromycin, clarithromycin), HIV protease inhibitors, calcium channel blockers (diltiazem, verapamil), nefazodone, and grapefruit juice also produce clinically significant increases.[32]
CYP3A4 inducers reduce midazolam efficacy. Rifampin reduces oral midazolam exposure to approximately 24% of normal values.[33] Carbamazepine, phenytoin, and St. John's Wort produce similar reductions.
Tricyclic antidepressant co-ingestion creates a specific reversal hazard: midazolam protects against TCA-induced seizures, so administering the reversal agent flumazenil in a patient who has also taken a TCA unmasks seizure and heart rhythm risks that may be fatal.[34]
Contraindications
Acute narrow-angle glaucoma is an absolute contraindication (benzodiazepine class effect).
Myasthenia gravis is an absolute contraindication — GABAergic muscle relaxation worsens the existing neuromuscular deficit, risking breathing failure.
Severe breathing insufficiency and obstructive sleep apnea are absolute contraindications for unsupervised use.
Known hypersensitivity to benzodiazepines contraindicates use.
Pregnancy (particularly first trimester) is a relative contraindication. Near-term use carries specific risks of neonatal sedation, low muscle tone, and breathing depression.
Concurrent CYP3A4 inhibitor use requires substantial dose reduction. Failure to adjust doses when starting potent inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors) has caused excessive sedation and breathing depression.[32]
Severe liver impairment requires dose reduction due to decreased clearance and increased free drug fraction.[20]
Severe kidney impairment requires dose reduction and enhanced monitoring due to accumulation of the active metabolite.[8]
Flumazenil must not be administered when tricyclic antidepressant co-ingestion is suspected or confirmed. Reversal of benzodiazepine-mediated seizure protection unmasks TCA-induced seizures and dangerous heart rhythms, which may be fatal.[34]
Harm Reduction[edit]
Forms & Identification
Midazolam circulates almost exclusively as diverted pharmaceutical product — manufactured tablets, oral syrup, and injectable solutions — rather than as illicitly synthesized material. The principal identification challenge is not adulterant testing but confirming the substance's identity against other benzodiazepines, which may differ dramatically in potency and duration.
Injectable vials should have intact seals, correct labeling, and pharmaceutical lot numbers. Loose tablets without original packaging carry higher risk of misidentification or degradation. Any tablet or solution of uncertain provenance should be treated as unverified.
Guidelines
- Start with the lowest available dose and allow full onset time before any redosing — midazolam's steep dose-response curve means small increases produce disproportionate effects
- Never use alone; ensure a sober, trusted companion is present throughout the experience and for at least two hours after apparent recovery
- Avoid eating a large meal within two hours of oral dosing to reduce nausea risk
- Do not drive, operate machinery, or make important decisions for at least 8 hours after administration
- If using a diverted pharmaceutical product, verify the identity and dose against a reliable reference before use
- Have flumazenil available if possible, but be aware it wears off faster than midazolam — resedation is possible
Set & Setting
Midazolam's reliable anterograde amnesia means the setting must be safe before the dose takes effect — the user will not be able to form judgments about changing conditions once amnesia onset occurs. A trusted, sober companion is essential, as amnesia may prevent recognizing dangerous situations or remembering to seek help.
The sedation-to-loss of consciousness continuum is steep with intravenous and intranasal routes. Oral administration provides a slower, more predictable onset. Regardless of route, the user should be in a physically safe environment: lying or reclined, away from hazards such as water, heights, or traffic.
Aftercare & integration. Anterograde amnesia is expected — the user may have no memory of events during the drug's action. A companion should debrief the person on what occurred, including any decisions made or documents signed during the amnestic window.
Physical recovery is typically rapid once sedation clears, but drowsiness and impaired coordination may persist for several hours beyond apparent alertness. Sleep, hydration, and a light meal support recovery. Cognitive sharpness — particularly short-term memory function — may take 12–24 hours to fully normalize.
Recovery & Support
Benzodiazepine dependence develops gradually and is often recognized only when a missed dose triggers withdrawal symptoms — anxiety, insomnia, tremors, and sensory hypersensitivity. Midazolam's short half-life means withdrawal symptoms can emerge within hours of the last dose, making it among the more difficult benzodiazepines to discontinue abruptly.
Abrupt cessation after chronic use is dangerous and potentially fatal due to seizure risk. Medical supervision is essential for any taper. Standard approaches involve switching to a long-acting benzodiazepine (diazepam or clonazepam) and tapering gradually over weeks to months. Support resources include the SAMHSA National Helpline (1-800-662-4357) and the Benzodiazepine Information Coalition (benzoinfo.com) for peer support and taper guidance.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Slow, shallow, or stopped breathing (fewer than 10 breaths per minute)
- Blue or grey discoloration of lips or fingertips
- Unresponsive to voice or firm physical stimulation
- Seizures (if in withdrawal)
- Persistent vomiting while sedated (choking risk)
Immediate steps:
- Call emergency services immediately if breathing is slow, absent, or the person is unresponsive
- Place the person in the recovery position (on their side) to prevent choking
- Tilt the head back slightly to keep the airway open
- If breathing stops and you are trained, begin rescue breathing
- Do NOT induce vomiting
- Do NOT leave the person alone
What to tell the dispatcher: the substance taken (midazolam/Versed), approximate dose and time, any other substances involved, and current symptoms — especially breathing rate. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
Reversal agent: Flumazenil reverses benzodiazepine effects. Standard initial dose is 0.2 mg IV. Its effects last only 30–60 minutes — shorter than midazolam — so monitor for resedation for at least 2 hours.[35] Do not administer flumazenil if the person may have also taken a tricyclic antidepressant — this can trigger fatal seizures.[34]
Legal Status[edit]
Midazolam is a controlled substance in all major jurisdictions, reflecting the standard regulatory posture toward benzodiazepines: recognized medical utility combined with established abuse and dependence potential. Its placement on the WHO Model List of Essential Medicines underscores its clinical importance despite controlled status.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | Prescription required; standard benzodiazepine scheduling[10] |
| United Kingdom | Schedule 3 / Class C (Misuse of Drugs Act 1971) | Prescription-only medicine |
| Australia | Schedule 8 (Controlled Drug of Addiction) | Stricter than most benzodiazepine scheduling; reflects clinical potency and abuse concerns[36] |
| Canada | Controlled Drugs and Substances Act | Federal controlled substance; prescription required[37] |
| European Union | Prescription-only medicine | Regulated nationally under each member state's controlled substance framework |
| International | WHO Model List of Essential Medicines | Recognized as essential for sedation, anesthesia, and seizure management |
Australia's Schedule 8 classification is notably stricter than most jurisdictions' benzodiazepine scheduling. The U.S. Schedule IV placement is shared with all other approved benzodiazepines — a relatively permissive controlled status, though prescribing, dispensing, and refill restrictions still apply.
references
- [1] ^abKhanderia U, Pandit SK (1987) Use of midazolam hydrochloride in anesthesia. — Clinical pharmacy PMID:3319363
- [2] ^abPhilip AB, Brohan J, Goudra B (2025) The Role of GABA Receptors in Anesthesia and Sedation: An Updated Review. — CNS drugs doi:10.1007/s40263-024-01128-6
- [3] ^abcdOlkkola KT, Ahonen J (2008) Midazolam and other benzodiazepines. — Handbook of experimental pharmacology doi:10.1007/978-3-540-74806-9_16
- [4]
- [5] ^abcWheless JW (2021) A critical evaluation of midazolam nasal spray for the treatment of patients with seizure clusters. — Expert review of neurotherapeutics doi:10.1080/14737175.2021.1890033
- [6] ^abcFoitzick MF, Medina NB, Iglesias Garcia LC, Gravielle MC (2020) Benzodiazepine exposure induces transcriptional down-regulation of GABAA receptor alpha1 subunit gene via L-type voltage-gated calcium channel activation. — Neuroscience letters doi:10.1016/j.neulet.2020.134801